Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut microbiome. In this open-label, single-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dizman, Nazli, Meza, Luis, Bergerot, Paulo, Alcantara, Marice, Dorff, Tanya, Lyou, Yung, Frankel, Paul, Cui, Yujie, Mira, Valerie, Llamas, Marian, Hsu, Joann, Zengin, Zeynep, Salgia, Nicholas, Salgia, Sabrina, Malhotra, Jasnoor, Chawla, Neal, Chehrazi-Raffle, Alex, Muddasani, Ramya, Gillece, John, Reining, Lauren, Trent, Jeff, Takahashi, Motomichi, Oka, Kentaro, Higashi, Seiya, Kortylewski, Marcin, Highlander, Sarah K., Pal, Sumanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018425/
https://www.ncbi.nlm.nih.gov/pubmed/35228755
http://dx.doi.org/10.1038/s41591-022-01694-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018425/
https://www.ncbi.nlm.nih.gov/pubmed/35228755
http://dx.doi.org/10.1038/s41591-022-01694-6

Ejemplares similares